Takeda Pharmaceutical Company Limited (TAK)Healthcare | Drug Manufacturers - Specialty & Generic | Chuo, Japan | NYSE
19.67 USD
+0.22
(1.131%)
⇧
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 19.67 |
Hot Take ↕ | Oct. 10, 2026, 3:57 a.m. EDT
The investment case here is fundamentally broken by a deteriorating business trajectory masked by a massive debt burden. While the company boasts a strong 'Buy' rating from analysts and a recent revenue bump, the price history tells a different story: a nearly 42% collapse over the last nine years, capped by two consecutive years of negative growth. This is not a value trap; it is a structural decline where the market has correctly priced out the risk of a shrinking franchise. The balance sheet is a ticking time bomb, with debt nearly ten times the equity base, making any future growth attempt financially perilous. Short-term, the stock is merely a speculative play on a turnaround that the options market is actively betting against. The heavy put open interest suggests traders expect further downside, ignoring the analyst hype. The dividend yield of 3.36% is misleading; it is not a reliable income stream given the negative return on equity and the precarious debt situation. Investors should avoid this security until the debt load is meaningfully reduced and the multi-year decline is reversed, which currently looks like a distant prospect. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.051325 |
| AutoTheta | 0.051421 |
| AutoETS | 0.057959 |
| AutoARIMA | 0.057959 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 54% |
| H-stat | 2.63 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.510 |
| Excess Kurtosis | 0.63 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2026-03-30 |
| Last Dividend Date | 2025-03-30 |
| Debt to Equity Ratio | 73.245 |
| Revenue per Share | 1462.7435 |
| Market Cap | 62,837,235,712 |
| Forward P/E | 37.11 |
| Beta | 0.10 |
| Profit Margins | -3.54% |
| Website | https://www.takeda.com |
As of Oct. 10, 2026, 3:57 a.m. EDT: Speculators are positioning for continued weakness with heavy out-of-the-money put volume relative to calls across all expirations. The open interest is overwhelmingly concentrated in deep strikes (15.0), suggesting a 'bet against' strategy rather than a hedge. Call activity is sparse and mostly centered on the money or slightly out, indicating a lack of aggressive bullish conviction despite the strong analyst consensus.
| Date | Dividend | Yield % |
|---|---|---|
| 2025-03-31 | 0.339 | 2.279758 |
| 2024-09-30 | 0.326 | 2.292546 |
| 2024-03-27 | 0.292 | 2.057787 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.397017 |
| Address1 | 1-1, Nihonbashi-Honcho 2-chome |
| All Time High | 31.29 |
| All Time Low | 12.28 |
| Ask | 19.9 |
| Ask Size | 8,400 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 3,133,750 |
| Average Daily Volume3 Month | 2,946,754 |
| Average Volume | 2,946,754 |
| Average Volume10Days | 3,133,750 |
| Beta | 0.1 |
| Bid | 19.55 |
| Bid Size | 12,300 |
| Book Value | 15.120108 |
| City | Chuo |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Country | Japan |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 19.67 |
| Current Ratio | 1.14 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 19.705 |
| Day Low | 19.565 |
| Debt To Equity | 73.245 |
| Display Name | Takeda Pharmaceutical |
| Dividend Date | 1,783,296,000 |
| Dividend Rate | 0.62 |
| Dividend Yield | 3.13 |
| Earnings Call Timestamp End | 1,746,698,400 |
| Earnings Call Timestamp Start | 1,746,698,400 |
| Earnings Growth | -0.098 |
| Earnings Quarterly Growth | -0.089 |
| Earnings Timestamp | 1,793,277,000 |
| Earnings Timestamp End | 1,793,277,000 |
| Earnings Timestamp Start | 1,793,277,000 |
| Ebitda | 1,249,335,967,744 |
| Ebitda Margins | 0.27048 |
| Enterprise To Ebitda | 4.113 |
| Enterprise To Revenue | 1.113 |
| Enterprise Value | 5,138,675,138,560 |
| Eps Forward | 0.53 |
| Eps Trailing Twelve Months | -0.34 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,774,915,200 |
| Exchange | NYQ |
| Exchange Data Delayed By | 20 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 18.335 |
| Fifty Day Average Change | 1.335001 |
| Fifty Day Average Change Percent | 0.07281162 |
| Fifty Two Week Change Percent | 39.7017 |
| Fifty Two Week High | 19.89 |
| Fifty Two Week High Change | -0.21999931 |
| Fifty Two Week High Change Percent | -0.0110608 |
| Fifty Two Week Low | 12.99 |
| Fifty Two Week Low Change | 6.6800003 |
| Fifty Two Week Low Change Percent | 0.51424176 |
| Fifty Two Week Range | 12.99 - 19.89 |
| Financial Currency | JPY |
| First Trade Date Milliseconds | 1,262,701,800,000 |
| Five Year Avg Dividend Yield | 4.4 |
| Float Shares | 3,156,801,399 |
| Forward Eps | 0.53 |
| Forward P E | 37.11321 |
| Free Cashflow | 541,443,883,008 |
| Full Exchange Name | NYSE |
| Full Time Employees | 47,029 |
| Fullday Change | 0.21999931 |
| Fullday Change Percent | 1.1311018 |
| Fullday Price | 19.67 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.64468 |
| Gross Profits | 2,977,719,910,400 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00075999997 |
| Held Percent Institutions | 0.03313 |
| Implied Shares Outstanding | 3,194,572,264 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ir Website | http://www.takeda.com/investor-information/ |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,743,379,200 |
| Last Dividend Value | 0.339 |
| Last Fiscal Year End | 1,774,915,200 |
| Long Business Summary | Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan. |
| Long Name | Takeda Pharmaceutical Company Limited |
| Market | us_market |
| Market Cap | 62,837,235,712 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_874540 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -163,436,003,328 |
| Next Fiscal Year End | 1,806,451,200 |
| Non Diluted Market Cap | 60,516,502,323 |
| Number Of Analyst Opinions | 3 |
| Open | 19.67 |
| Operating Cashflow | 953,630,982,144 |
| Operating Margins | 0.16445999 |
| Payout Ratio | 2.7989001 |
| Peg Ratio | 0.44 |
| Phone | 81 3 3278 2111 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 19.67 |
| Post Market Time | 1,792,187,096 |
| Previous Close | 19.45 |
| Price Hint | 2 |
| Price To Book | 1.3009167 |
| Price To Sales Trailing12 Months | 0.01360427 |
| Profit Margins | -0.035380002 |
| Quick Ratio | 0.513 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.219999 |
| Regular Market Change Percent | 1.1311 |
| Regular Market Day High | 19.705 |
| Regular Market Day Low | 19.565 |
| Regular Market Day Range | 19.565 - 19.705 |
| Regular Market Open | 19.67 |
| Regular Market Previous Close | 19.45 |
| Regular Market Price | 19.67 |
| Regular Market Time | 1,792,180,802 |
| Regular Market Volume | 2,718,107 |
| Return On Assets | 0.02694 |
| Return On Equity | -0.02262 |
| Revenue Growth | 0.102 |
| Revenue Per Share | 1,462.7435 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,193,502,878 |
| Shares Percent Shares Out | 0.00090000004 |
| Shares Short | 2,918,812 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,088,761 |
| Short Name | Takeda Pharmaceutical Company L |
| Short Percent Of Float | 0.00090000004 |
| Short Ratio | 1.28 |
| Source Interval | 15 |
| Symbol | TAK |
| Target High Price | 25.137035 |
| Target Low Price | 21.047054 |
| Target Mean Price | 22.75287 |
| Target Median Price | 22.074518 |
| Total Cash | 460,981,993,472 |
| Total Cash Per Share | 145.853 |
| Total Debt | 5,536,499,105,792 |
| Total Revenue | 4,618,934,812,672 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 200.0 |
| Trailing Annual Dividend Yield | 10.282776 |
| Trailing Eps | -0.34 |
| Trailing Peg Ratio | 0.4231 |
| Triggerable | 1 |
| Two Hundred Day Average | 17.3397 |
| Two Hundred Day Average Change | 2.3302994 |
| Two Hundred Day Average Change Percent | 0.13439098 |
| Type Disp | Equity |
| Volume | 2,718,107 |
| Website | https://www.takeda.com |
| Zip | 103-8668 |